What is the long-term vaccine effectiveness against SARS-CoV-2 infection? IUSPH medrxivpreprint SARSCoV2 COVID19 Vaccine VaccineEfficacy Effectiveness
By Suchandrima BhowmikJul 8 2022Reviewed by Aimee Molineux Massive vaccination programs throughout the world have led to significant protection against SARS-CoV-2 infection and severe diseases. However, there has been an increase in breakthrough infections during late 2021 and early 2022 among vaccinated individuals due to the replacement of the Delta variant with the Omicron variant.
About the study The study involved screening abstracts and titles of preprints and peer-reviewed journals in English for the identification of manuscripts on VE against SARS-CoV-2 infection as well as a symptomatic disease until 21st June 2022.
Related StoriesNo VE difference against Delta was observed at 9 months post-vaccination for ChAdOx1 nCoV-19 and mRNA-1273. However, a decline in VE was observed in the case of BNT162b2 against both Delta and Omicron infections. The VE against Omicron infection for three doses of BNT162b2 was observed to be 82.4%, 31.5%, and 19.0%, respectively at 14 days, at 6, and 9 months post administration of the last vaccine dose.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
The host cell membrane binding surfaces of SARS-CoV-2 spike variantsThe host cell membrane binding surfaces of SARS-CoV-2 spike variants UAlberta SARSCoV2 COVID19 coronavirus covid spike variants
Read more »
Association of periodic fasting with lower severity of COVID-19 outcomes in the SARS-CoV-2 prevaccine era: an observational cohort from the INSPIRE registry
Read more »
COVID-19 vaccination with bacterial peptide conjugated to receptor-binding domain elicits potent immune responseIn a new study, researchers assessed the efficiency of immunization with a bacterial peptide conjugated to the SARS-CoV-2 receptor-binding domain against SARS-CoV-2 infection.
Read more »
The host cell membrane binding surfaces of SARS-CoV-2 spike variantsThe host cell membrane binding surfaces of SARS-CoV-2 spike variants UAlberta SARSCoV2 COVID19 coronavirus covid spike variants
Read more »
Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study - BMC Infectious DiseasesBackground Convalescent plasma (CP) has been widely used to treat COVID-19 and is under study. However, the variability in the current clinical trials has averted its wide use in the current pandemic. We aimed to evaluate the safety and efficacy of CP in severe coronavirus disease 2019 (COVID-19) in the early stages of the disease. Methods A randomized controlled clinical study was conducted on 101 patients admitted to the hospital with confirmed severe COVID-19. Most participants had less than 14 days from symptoms onset and less than seven days from hospitalization. Fifty patients were assigned to receive CP plus standard therapy (ST), and 51 were assigned to receive ST alone. Participants in the CP arm received two doses of 250 mL each, transfused 24 h apart. All transfused plasma was obtained from
Read more »
Antonio Colak to Rangers confirmed as he makes title vow to 'incredible fans'The Croatian's forward has been long rumoured but he has now put pen to paper on a long-term deal to sign with the Ibrox club ahead of the new Premiership campaign.
Read more »